A cannabis-derived drug that could reduce opioid fentanyl use for breakthrough cancer pain is one step closer thanks to Health Canada approval that will allow a clinical trial to begin. Ontario-based Tetra Bio-Pharma announced on Friday that clinical data shows their new drug (PPP001) can bring rapid relief to patients’ suffering and may be a faster-acting alternative to opioid fentanyl. Interim CEO and chief scientific officer Dr. Guy Chamberland said it’s important to bring cannabinoid products to market in way that ensures “physicians who have been hesitant” will feel comfortable recommending it. “Medical cannabis may help reduce the use of drugs like fentanyl for treating breakthrough and chronic pain,” said. “However, unrefuted scientific data on its safety and effectiveness that will satisfy regulators, professional groups and insurers is what’s missing. “Tetra is in the business of providing that evidence which would see our drug PPP001 become a complementary prescription therapy. “ As a prescription drug with a Drug Identification Number, it will be eligible for insurance coverage, making the cannabis-based medication accessible in pharmacies. Patient recruitment will begin in October and the study will be conducted by Montreal-based Santé Cannabis. For more information on eligibility criteria etc. visit the Santé Cannabis website: www.santecannabis.ca/en/research/cannabis-clinical-trial/ or call 514-419-4131.
News 
Market Data 
Discover 
